Search
Dexlansoprazole
go.drugbank.com/drugs/DB05351ApprovedDexlansoprazole is a new-generation proton pump inhibitor (PPI) used for the management of symptoms associated with gastroesophageal reflux disease (GERD) and erosive esophagitis. … unique pharmacokinetic profile due to its delayed-release and dual-delivery release system: This aims to address some limitations of the older-generation PPIs, such as short plasma half-life and the need for
Categories: Drugs for Acid Related Disorders, Drugs for Peptic Ulcer and Gastro-Oesophageal Reflux Disease (Gord)Icatibant
go.drugbank.com/drugs/DB06196ApprovedInvestigational[A4017,A263046] Icatibant was approved by the FDA on August 25, 2011, and by the EMA in 2008 as a treatment for hereditary angioedema. … results obtained from 3 double-blind, randomized, controlled clinical trials known as FAST 1, 2, and 3, where a median time to almost complete symptom relief was observed to be 8 hours compared to 36 hours for
Categories: Bradykinin Receptor Antagonists, Bradykinin B2 Receptor AntagonistsFilgotinib
go.drugbank.com/drugs/DB14845ApprovedInvestigationalRheumatoid arthritis (RA) is a chronic, autoimmune, systemic, and inflammatory disease that causes synovial joint symptoms and can limit range of motion in severe cases. … [A189165] Filgotinib is currently reserved for patients who cannot tolerate DMARDs, or who have been unable to achieve remission in response to one or more DMARDs.[L16616]
Categories: P-glycoprotein substratesCyclizine
go.drugbank.com/drugs/DB01176ApprovedWithdrawnA histamine H1 antagonist given by mouth or parenterally for the control of postoperative and drug-induced vomiting and in motion sickness. (From Martindale, The Extra Pharmacopoeia, 30th ed, p935)
Categories: Antihistamines for Systemic Use, Cytochrome P-450 CYP2C9 InhibitorsSodium oxybate
go.drugbank.com/drugs/DB09072ApprovedInvestigationalin May 2023. … [L30598] An extended-release oral suspension formulation of sodium oxybate for narcolepsy, marketed under the brand name LUMRYZ, gained tentative FDA approval in July 2022 [L42645] and was fully approved
Isoetharine
go.drugbank.com/drugs/DB00221ApprovedIsoetharine is a fast-acting bronchodilator used for emphysema, bronchitis and asthma.[A330]
Categories: Adrenergics for Systemic Use, Drugs for Obstructive Airway DiseasesCalcium polycarbophil
go.drugbank.com/drugs/DB14684ApprovedThis drug may also be used to help relieve the symptoms of irritable bowel syndrome or diarrhea. … Less gas and bloating compared to psyllium laxative products, but can cause heartburn, and belly cramps. It is insoluble in water, dilute acids, and dilute alkali.
Categories: Drugs for ConstipationPhenindamine
go.drugbank.com/drugs/DB01619ApprovedAntihistamines such as phenindamine appear to compete with histamine for histamine H1- receptor sites on effector cells. … Phenindamine is an antihistamine. Phenindamine blocks the effects of the naturally occurring chemical histamine in your body.
Categories: Antihistamines for Systemic UseTisotumab vedotin
go.drugbank.com/drugs/DB16732ApprovedInvestigationalIt is also being investigated for the combination use with other chemotherapeutic agents for recurrent or metastatic cervical cancer.[A238924] … This is the first and only approved antibody-drug conjugate for this therapeutic indication.
Categories: P-glycoprotein substrates, Cytochrome P-450 Substrates